Recombinant antibody technology has been leveraged to mitigate a range of common problems associated with hybridoma platforms, helping to facilitate the development of an entirely new class of ...

The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...

This article examines key innovations driving scalable, high-yield purification of recombinant AAVs and how they’re helping ...

Recombinant antibody technology has addressed many problems associated with hybridoma-based platforms, opening the door to a new class of biologics. Today, this technology continues to contribute to ...

The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein folding and post-translational modification factors that shape the ...

One of the greatest transformations in modern medicine arguably began with a corned beef sandwich. It was the late 1960s, and new Department of Medicine Chair Lloyd Hollingsworth “Holly” Smith Jr., MD ...

Epigenome editing has followed a similar path, in that more recent technological breakthroughs have enabled scientists to apply the discoveries made in previous decades. Epigenome editing performs a ...

CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies ...